戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              IL-4R and PRLR gave only small numbers of thymocytes, wh
2                                              IL-4R bound to the IL-13/IL-13Ralpha1 complex with slow
3                                              IL-4R is functional because IL-4 strongly induced activa
4                                              IL-4R is up-regulated during T cell differentiation by a
5                                              IL-4R signaling impaired the capacity of Treg cells to s
6                                              IL-4R-independent proliferation was controlled by a rise
7 tively activated macrophages, but the type 1 IL-4R is also important.
8        Thus, IL-4, acting through the type 1 IL-4R, induces Stat6-dependent IFN-gamma secretion by NK
9 n mice bred to have null mutations of IL-13, IL-4R(alpha), or STAT-6, transgenic IL-10 did not induce
10 n and fibrosis being independent of an IL-13/IL-4R(alpha)/STAT-6 activation pathway.
11    Binding of IL-4 by either the type 1 or 2 IL-4R, or of IL-13 by the type 2 IL-4R, initiates Jak-de
12      IL-13, which signals through the type 2 IL-4R and mimics many IL-4 effects, failed to stimulate
13 thymic microenvironment expresses the type 2 IL-4R complex and is functionally responsive to its know
14  to the IL-13Ralpha1 component of the type 2 IL-4R that is linked to STAT6.
15 e contribution of IL-13 acting at the type 2 IL-4R to immune and functional responses to primary (Hb1
16  of the IL-4R, and IL-13 binds to the type 2 IL-4R, IL-13 has been proposed as an inhibitor that bloc
17 type 1 or 2 IL-4R, or of IL-13 by the type 2 IL-4R, initiates Jak-dependent tyrosine phosphorylation
18 ed phosphorylation of Janus kinases 1 and 3, IL-4R alpha, signal transducer and activator of transcri
19  interferon-gamma (IFNGR) and interleukin 4 (IL-4R) cytokine receptors, in particular, direct the ear
20   We found that receptors for interleukin-4 (IL-4R) are highly expressed in H-RS cells.
21 and type II (IL-4R alpha/IL-13R alpha1/IL-4, IL-4R alpha/IL-13R alpha1/IL-13) ternary signaling compl
22 Th1/2 lineage commitment genes (GATA3, IL-4, IL-4R, STAT4 and TBET) in umbilical cord DNA at birth in
23          These results demonstrate that IL-4/IL-4R interactions on CD8+ T cells play a critical role
24 rocess is critically dependent upon the IL-4/IL-4R signaling pathway.
25  expression activities to a minimally active IL-4R mutant, delta 557.
26                                     Although IL-4R alpha signals Shc and SH2-containing inositol phos
27                                     Although IL-4R(-/-) mice displayed a milder course throughout, th
28 tion of V75R576 resulted in expression of an IL-4R alpha with enhanced sensitivity to IL-4.
29                          Co-expression of an IL-4R antagonist by the rFPV vaccine further enhanced th
30 hance nuclear GATA-3 accumulation through an IL-4R-dependent action, leading to Th2 differentiation.
31 nt common component shared between IL-13 and IL-4R.
32 e in the binding affinity of both IL-13R and IL-4R complexes.
33 ming a ternary complex with IL-13Ralpha1 and IL-4R.
34 nsic and requires the expression of IL-4 and IL-4R.
35 ugh CD40 signaling can reverse both BCR- and IL-4R-mediated B7h down-regulation.
36 6 impaired the association of IL-2R beta and IL-4R alpha chains with Jak1 but did not have a major im
37 gamma R alpha, IL-10R alpha, IL-2R beta, and IL-4R alpha.
38 L-4R alpha/common gamma-chain (gamma(c)) and IL-4R alpha/IL-13R alpha1, and only the latter is also a
39 o known that the mechanism by which CD40 and IL-4R stimulation on a B cell increases the level of IgG
40  unaffected, but synergism between CD40- and IL-4R-mediated signals is completely ablated.
41 henotype and expressed Kit, FcepsilonRI, and IL-4R on their surface.
42    Thus, functional synergy between Flt3 and IL-4R signaling is critical for Stat-mediated regulation
43 tor, interleukin-2R gamma (IL-2R gamma), and IL-4R alpha.
44 nti-IL-10R-treated IL-4R alpha(-/-) mice and IL-4R alpha x IL-10 double knockouts.
45 ibroblasts showed nearly identical PDGFR and IL-4R activation, gross substrate tyrosine phosphorylati
46 peripheral B cells via the CD40 receptor and IL-4R together lead to IgE synthesis and secretion, but
47 ion, Dectin-1, CD206 (mannose receptor), and IL-4R.
48 s metaplasia and methacholine responses, and IL-4R null mice failed to show RV-induced mucous metapla
49 ing insulin receptor substrate 1/2, Shc, and IL-4R interacting protein, as well as Stat6.
50 lso increases the expression of TGFbetaR and IL-4R, pivotal to Th9 polarization.
51 ducing susceptibility to LV39, wild-type and IL-4R alpha(-/-) mice were treated with anti-IL-10R mAb,
52 responses, through administration of an anti-IL-4R alpha mAb, reversed asthma-like symptoms, when giv
53 tion-dependent and could be reversed by anti-IL-4R Abs.
54 f Vgamma2Vdelta2 T cells was blocked by anti-IL-4R alpha mAb but not anti-IL-4 mAb.
55 unction were attenuated or prevented by anti-IL-4R mAb.
56 cade, three anti-IL-5 biologics and one anti-IL-4R biologic have recently emerged as promising treatm
57                            Anti-IL-4 or anti-IL-4R Ab did not diminish IL-4 production by Th2 cells i
58 se using the JAK inhibitor AG490 or the anti-IL-4R(alpha) Ab M1 abrogated the persistence of phosphor
59 n and later reinfected and treated with anti-IL-4R mAb, an antagonist of IL-4 and IL-13 receptor bind
60 sed mRNA for IL-4R beta chain (also known as IL-4R alpha) and IL-13R alpha' chain (also known as IL-1
61 ibody to the IL-4Ralpha chain (also known as IL-4R beta) in surgical/biopsy samples of brain tumor ti
62 arrier populations by selectively augmenting IL-4R alpha-dependent signaling.
63 ing transgenic mice expressing an IL-2R beta/IL-4R alpha chimeric cytokine receptor transgene specifi
64 rotection, CIA was exacerbated in IL-2R beta/IL-4R alpha chimeric receptor transgenic mice, with incr
65  understanding of receptor crosstalk between IL-4R and BCR is summarized along with several possible
66 tor alpha chain (IL-4Ralpha), common to both IL-4R complexes: type 1 (IL-4Ralpha/gammac; IL-4 specifi
67                               Membrane-bound IL-4R mRNA expression was significantly elevated 7 days
68 trast to the lack of resistance conferred by IL-4R alpha gene deletion, partial resistance to LV39 wa
69 gulated in susceptible mice and inhibited by IL-4R-signaling in vitro, uncoupling parasite killing fr
70 s in the interleukin-4 receptor alpha chain (IL-4R alpha) have been linked to asthma incidence and se
71 BALB/c mice deficient for IL-4R alpha-chain (IL-4R alpha), while substrain IR173 was highly controlle
72 ed through a high affinity receptor complex (IL-4R).
73 be an important feedback mechanism to dampen IL-4R signaling in airway inflammation.
74            The ability of tyrosine-deficient IL-4Rs to mediate proliferative signaling and STAT phosp
75 pancreatic samples express no or low-density IL-4R.
76 -12 priming does not suppress IL-4-dependent IL-4R up-regulation shows that both IL-4 mRNA and cytoki
77 tein kinase C activation and STAT6-dependent IL-4R signaling.
78 cineurin pathway contribute to desensitizing IL-4R.
79 tive for cell types expressing the different IL-4Rs.
80 ise questions about the importance of direct IL-4R effects on smooth muscle in murine asthma models a
81 ch has previously been shown to downregulate IL-4R subunit alpha cell surface expression and promote
82 rs demonstrating significantly higher DUOX2, IL-4R, and IL-17RA expression in tumors than in adjacent
83 n helminth-infected mice deficient in either IL-4R alpha-chain or Stat6.
84       This action is not dependent on either IL-4R or IL-2R signals and results in OX40 controlling i
85 rastingly, there was no evidence that either IL-4R-dependent or IL-4R-independent/CCR3/IL-5-dependent
86  express high levels of endogenously encoded IL-4Rs.
87 recombinant Fowl Pox Virus (FPV)-gag pol env-IL-4R antagonist prime, intramuscular (i.m.) recombinant
88 ndicate that airway epithelial cells express IL-4R constitutively and that IL-4 directly induces the
89 ivo, mouse airway epithelial cells expressed IL-4R constitutively, and IL-4 (250 ng) increased MUC5 g
90 airway epithelial cells (NCI-H292) expressed IL-4R constitutively, and IL-4 (10 ng/ml) induced MUC2 g
91                   The viral vector-expressed IL-4R antagonist transiently inhibited IL-4/IL-13 signal
92 ed by local macrophage populations following IL-4R-dependent in situ proliferation and alternative ac
93 healing lesions in BALB/c mice deficient for IL-4R alpha-chain (IL-4R alpha), while substrain IR173 w
94 nd neck cancer cell lines expressed mRNA for IL-4R beta chain (also known as IL-4R alpha) and IL-13R
95 trovirus containing a mutant of the human (h)IL-4R alpha-chain, Y497F, which is unable to recruit the
96  analyses have identified RAS/NF1, hedgehog, IL-4R, and ALK pathway abnormalities as potential therap
97 4(+) T cells that induced IL-4 receptor(hi) (IL-4R(hi)) CD206(+) alternatively activated macrophages.
98 iched with CD21(low), CD11c(+), FCRL4(high), IL-4R(low) memory B cells.
99                 A mutation in the human (hu) IL-4R alpha, Q576R, has been linked with allergy in huma
100  IL-4 signaling through the endogenous human IL-4R(alpha).
101  functional consequences of two of the human IL-4R alpha allelic variants that have been found to ass
102 (IL-4R) type, IL-4Ralpha/IL-2Rgamma (class I IL-4R), whereas endothelial cells express another type,
103 e that gammadelta17 cells express the type I IL-4R and that STAT6 signaling negatively regulates gamm
104 er the common gamma-chain to form the type I IL-4R or with the IL-13R alpha1 chain (IL-13Ralpha1) to
105 ells responded to murine IL-4 via the type I IL-4R, but were unresponsive to IL-13, and did not expre
106 al structures of the complete set of type I (IL-4R alpha/gamma(c)/IL-4) and type II (IL-4R alpha/IL-1
107 other type, IL-4Ralpha/IL-13Ralpha (class II IL-4R).
108 ha1 chain (IL-13Ralpha1) to form the type II IL-4R.
109 entially regulated by the type I and type II IL-4R.
110 d highlight unforeseen roles for the type II IL-4R.
111 e role of IL-13Ralpha1 and the type I and II IL-4Rs in experimental asthma, we examined lung patholog
112 e I (IL-4R alpha/gamma(c)/IL-4) and type II (IL-4R alpha/IL-13R alpha1/IL-4, IL-4R alpha/IL-13R alpha
113 rom Flt3 ligand-deficient mice have impaired IL-4R signaling, with reduced phosphorylation of signal
114 diated suppression of L-CNV was abrogated in IL-4R-deficient mice and in bone marrow chimeras reconst
115 emonstrating that a functional alteration in IL-4R alpha requires the coexistence of two naturally oc
116 ative to wild-type or littermate controls in IL-4R alpha(-/-) mice with complementary defects in IL-1
117 atment further suppressed parasite growth in IL-4R alpha(-/-) mice infected with L. major IR173.
118 17A production, but this was not observed in IL-4R KO and STAT6 KO mice.
119  the size of the VM population is reduced in IL-4R-deficient animals.
120 ephalomyelitis and enhanced remyelination in IL-4R(-/-) mice appeared to be related to a shift toward
121  the importance of juxtatyrosine residues in IL-4R signaling and argue for an essential role of exten
122      To directly assess the role of STAT6 in IL-4R- and CD40-mediated germline transcription and swit
123 ts show that hypoxia significantly increased IL-4R alpha expression in wild-type (WT) control lungs.
124           The cytokine receptor interleukin (IL)-4R, expressed by lymphocytes, is well known for its
125  IL-4 production and requires MPhi-intrinsic IL-4R signaling.
126 d from T15 had enzymatic activity and killed IL-4R+ C1498 cells, but not IL-4R- EL4 cells.
127    In the T cell line CTLL2, ligation of kit/IL-4R alpha induces cellular proliferation.
128                 SCF-mediated ligation of kit/IL-4R alpha is sufficient to elicit IL-4-specific gene e
129 f cells expressing the chimeric receptor kit/IL-4R alpha with SCF induces activation of the IL-4R alp
130 t examined the genetics of five of the known IL-4R alpha allelic variants in asthmatic and nonatopic
131  to IL-4 because expression of both membrane IL-4R and the IL-4-neutralizing soluble (s)IL-4R were re
132 single nebulized dose of IL-4R 1,500 microg, IL-4R 500 microg, or placebo after stopping inhaled cort
133 urce of IL-4 receptor (IL-4R) that mobilizes IL-4R signaling pathways and the transcription factor GA
134                    This vector-based mucosal IL-4R antagonist/SOSIP booster strategy, which promotes
135                     Administration of murine IL-4R antagonist during allergen (OVA) challenge inhibit
136                      Each form of the murine IL-4R(alpha) mediated tyrosine phosphorylation of STAT6
137 e human monocytic cell line U937 with murine IL-4R(alpha) cDNA bearing the I or V at position 50 and
138                                    Nebulized IL-4R has a serum half-life of approximately 1 wk.
139  Thus, through different mechanisms, neither IL-4R nor IL-12R has any clear advantage in polarizing c
140 , although IL-4Ralpha mRNA was expressed, no IL-4R protein was detectable in two adult and one pediat
141 ivity and killed IL-4R+ C1498 cells, but not IL-4R- EL4 cells.
142  levels of IFN-gamma and IL-12Rbeta2 but not IL-4R.
143                    Selective augmentation of IL-4R signaling in Treg cells induced their reprogrammin
144 fection experiments with different chains of IL-4R and kinase-deficient JAK1 and JAK2 mutants in CHO
145 h respond to IL-13, gammac is a component of IL-4R but does not appear to be a component of IL-13R.
146 lomyelitis in mice demonstrating deletion of IL-4R and found a correlation with cytokine expression d
147 ls of the primary structural determinants of IL-4R-mediated proliferative signaling.
148 signed to receive a single nebulized dose of IL-4R 1,500 microg, IL-4R 500 microg, or placebo after s
149                Conclusions: A single dose of IL-4R appears safe and effective in moderate asthma.
150 tat6, the transcription factor downstream of IL-4R that is required for Th2 differentiation.
151 ocess is mediated by continued engagement of IL-4R(alpha), suggesting enhanced responses of V50 IL-4R
152 sion of IL-13R alpha1 and mRNA expression of IL-4R alpha compared with Th0, Th1, or Th2 polarized cel
153                We examined the expression of IL-4R by using a monoclonal antibody to the IL-4Ralpha c
154 hese results establish uniform expression of IL-4R on head and neck cancer cell lines and IL-4 toxin
155                   In addition, expression of IL-4R on the cell surface of various normal brain tissue
156 Th cells instead show elevated expression of IL-4R subunit alpha on cell surface, sensitized IL-4/STA
157 ny studies have implicated the importance of IL-4R alpha in the development of allergic inflammation
158  CD4 cells can secrete IL-4 independently of IL-4R signals, but how this secretion is regulated is no
159 tiated WT Th1 cells was not due to a lack of IL-4R expression or phosphorylation.
160  B cells had a significantly higher level of IL-4R and CD23 expression than B7.1+ B cells.
161 tested (n = 7) expressed no or low levels of IL-4R.
162 ted regarding IL-4R, the exact mechanisms of IL-4R-mediated signaling pathways in human B cells are n
163 ors; however, prior engagement of CD40 or of IL-4R produces an alternate signaling pathway in which B
164 rine-rich ID-1 region in this new program of IL-4R signal transduction observed in activated T cells.
165 nine substitution at position 576 (Q576R) of IL-4R alpha has been associated with severe asthma, espe
166 play an important role for the regulation of IL-4R-mediated JAK/STAT signaling.
167 ut not IFN-gamma, suggested a direct role of IL-4R-mediated events.
168 ounting for this result were the strength of IL-4R and CD40 signaling and relative rates of cell prol
169 he investigation of the subunit structure of IL-4R demonstrated that head and neck cancer cell lines
170 ining domains within the cytoplasmic tail of IL-4R alpha play in IL-4-mediated protection from apopto
171 pe II alveolar epithelial cell expression of IL-4Rs in mice sensitized and challenged with Af, and in
172 d STAT1, whereas PD-L2 expression depends on IL-4R alpha and STAT6.
173  that gammac is not a component of IL-13R or IL-4R systems in these cells.
174 that block binding to either IL-13Ralpha1 or IL-4R inhibited the TR-FRET signal formed by the ternary
175 hibited by costimulation with either CD40 or IL-4R.
176 s no evidence that either IL-4R-dependent or IL-4R-independent/CCR3/IL-5-dependent immunity influence
177 expression in DCs developed from STAT6-/- or IL-4R alpha-/- mice.
178 ected in mice deficient in IL-4 synthesis or IL-4R triggering.
179  that human brain tumors in situ overexpress IL-4R compared with normal brain tissues, thus confirmin
180           However, during the chronic phase, IL-4R(-/-) mice exhibited extensive remyelination and an
181 bound less effectively to the phosphorylated IL-4R/GST fusion protein than that in IFNGR(-/-) Th1 cel
182 Modified Vaccinia Ankara Virus (MVA)-gag pol-IL-4R antagonist boost followed by an i.m SOSIP-gp140 bo
183  murine IL-4 mutant (C118 deletion) protein (IL-4R antagonist) inhibited IL-4- and IL-13-induced STAT
184            These data suggest that the Q576R IL-4R alpha- chain polymorphism may mitigate disease exp
185  their expression of interleukin-4 receptor (IL-4R) and IL-13R subunits.
186 d IL-13 and the heterodimeric IL-4 receptor (IL-4R) complexes that they interact with play a key role
187                           The IL-4 receptor (IL-4R) in B cells is composed of two chains, the IL-4-bi
188                  The interleukin 4 receptor (IL-4R) is a central mediator of T helper type 2 (T(H)2)-
189        We found that interleukin 4 receptor (IL-4R) knockout and downstream signal transducer and act
190 n of the alpha-subunit of the IL-4 receptor (IL-4R) might be relatively resistant to the gain-of-func
191 nd based on the expression of IL-4 receptor (IL-4R) on most acute myeloid leukemia cases.
192 ) mice with enhanced interleukin-4 receptor (IL-4R) signaling exhibited STAT6-dependent impaired gene
193 ng damage, whereas subsequent IL-4 receptor (IL-4R) signaling reduced elevations in IL-17 mRNA levels
194 that dimerization of Interleukin-4 receptor (IL-4R) subunits is a pivotal step for JAK/STAT signal tr
195 tion is driven by a source of IL-4 receptor (IL-4R) that mobilizes IL-4R signaling pathways and the t
196  to IL-4, T cells express one IL-4 receptor (IL-4R) type, IL-4Ralpha/IL-2Rgamma (class I IL-4R), wher
197 17 cells expressed the type I IL-4 receptor (IL-4R), and IL-4 increased STAT6 phosphorylation in gamm
198            To target interleukin-4 receptor (IL-4R), we used a recombinant protein fusing circularly
199 ss a high density of interleukin-4 receptor (IL-4R), whereas normal ovarian tissues tested (n = 7) ex
200 rate- to high-density surface IL-4 receptor (IL-4R), whereas normal pancreatic samples express no or
201 and IL-13 activate the type 2 IL-4 receptor (IL-4R), which contains the IL-13Ralpha1 and IL-4Ralpha c
202 xpress high affinity interleukin-4 receptor (IL-4R), which is an attractive target for receptor-direc
203                               IL-4 receptor (IL-4R)-deficient CD8+ T cells specific for the circumspo
204     Soluble recombinant human IL-4 receptor (IL-4R; Nuvance; altrakincept) inactivates naturally occu
205 l lines also express surface IL-4 receptors (IL-4R) and IL-4 binds to IL-4R on one cell line studied
206  of plasma membrane interleukin-4 receptors (IL-4R).
207                              IL-4 receptors (IL-4Rs) are also expressed by nonhematopoietic cells as
208                     Although IL-4 receptors (IL-4Rs) but not IL-12Rs are expressed on naive CD4(+) T
209 Although IL-4 signals through two receptors, IL-4R alpha/common gamma-chain (gamma(c)) and IL-4R alph
210 omain with that of other cytokine receptors: IL-4R, IL-9R, and prolactin receptor (PRLR).
211 lth of information has accumulated regarding IL-4R, the exact mechanisms of IL-4R-mediated signaling
212 uncharacterized role for STUB1 in regulating IL-4R signaling, which might provide a new strategy for
213  by IL-4 treatment, and this effect requires IL-4R.
214 bition of inflammatory cytokines in resident IL-4R-expressing epidermal cells and thereby alters the
215 e IL-4R and the IL-4-neutralizing soluble (s)IL-4R were reduced in Il21r(-/-) mice.
216       A haplotype analysis revealed a single IL-4R alpha haplotype that was associated with allergic
217 ombination therapy between IL-12 and soluble IL-4R (sIL-4R) on the established infection of HSV-1 in
218 ys after conidia challenge; however, soluble IL-4R mRNA expression was increased 30 days after conidi
219  the anti-inflammatory activities of soluble IL-4R (sIL-4R).
220 s are arrested at the double-negative stage, IL-4R, IL-9R, or PRLR all imparted some progression to t
221 10 was not due to down-regulation of surface IL-4R because pretreatment with these cytokines did not
222                                    To target IL-4R, we have developed IL-4 cytotoxin, in which circul
223 t during chronic filarial infection and that IL-4R-independent/IL-5- and CCR3-dependent pathways are
224 hus confirming our previous conclusions that IL-4R in brain tumors may serve as an attractive target
225 e cell analysis experiments demonstrate that IL-4R/Stat6 signaling, while influencing the final frequ
226                  These results indicate that IL-4R-targeted cytotoxin may be a useful agent for the m
227                  In this study, we show that IL-4R is expressed by breast and ovarian cancer cell lin
228 y analysis at the plasma membrane shows that IL-4R subunit dimerization is indeed a strictly ligand-i
229                      These data suggest that IL-4R exerts a negative regulatory role on oligodendrocy
230                                          The IL-4R alpha-chain (IL-4Ralpha) contains a putative ITIM
231                                          The IL-4R induces proliferation and gene expression through
232 ponents of a receptor complex for IL-13, the IL-4R and a low affinity IL-13-binding chain, IL-13R alp
233                     In response to IL-4, the IL-4R activates a set of phosphotyrosine binding domain-
234 i-IL-10R mAb, and in a genetic approach, the IL-4R alpha(-/-) mice were crossed with BALB/c IL-10(-/-
235  assay targeting the interaction between the IL-4R and the binary complex.
236 sed levels of IL-4 could be explained by the IL-4R being unavailable to neutralize this cytokine in I
237 lity is that in the absence of gamma(c), the IL-4R alpha chain is able to transduce signals by homodi
238 es, suggesting a direct contribution for the IL-4R pathway to the heightened susceptibility of co-inf
239  overlap of their functions results from the IL-4R alpha-chain forming an important functional signal
240                              Patients in the IL-4R 1,500 microg group also required significantly les
241 ithdrawal of corticosteroids, but not in the IL-4R 500 microg group or the placebo group (p < 0.05).
242 at an additional level of specificity in the IL-4R signaling mechanism exists and may partially expla
243 eral commonly occurring polymorphisms in the IL-4R(alpha) have been associated with atopy in humans;
244  complex receptor system, which includes the IL-4R alpha-chain, IL-4Ralpha, and at least two other ce
245              Memory CD8+ T cells lacking the IL-4R are unable to establish a stable population residi
246                            Engagement of the IL-4R activates multiple signaling pathways, including t
247 through a receptor complex consisting of the IL-4R alpha chain and the common gamma chain (gamma c),
248 cytoplasmic and transmembrane domains of the IL-4R alpha chain was generated.
249 -4R alpha with SCF induces activation of the IL-4R alpha-associated kinase JAK-1 and the transcriptio
250 chanisms of binding and stabilization of the IL-4R and IL-13R complexes, we compared the effects of s
251                              Analyses of the IL-4R in factor-dependent cell lines led to the developm
252 lpha' is a novel functional component of the IL-4R system and that JAK1 and JAK2 mediate IL-4-induced
253 ed gammac) is shown to be a component of the IL-4R system, whereas in nonhematopoietic cells, gammac
254  IL-13Ralpha' forms a novel component of the IL-4R system.
255 c is absent and it is not a component of the IL-4R system.
256 )2 protein and the cytoplasmic domain of the IL-4R(alpha) chain that harbors the Stat6 docking sites.
257 m resides in the extracellular domain of the IL-4R(alpha).
258 ecause STAT6 is a downstream effector of the IL-4R, and IL-13 binds to the type 2 IL-4R, IL-13 has be
259  (gamma(c)) is a functional component of the IL-4R, yet cells lacking gamma(c) are able to respond to
260    Together, these data demonstrate that the IL-4R alpha cytoplasmic domain is sufficient to activate
261                   Further, we found that the IL-4R gene regulation domain (amino acids 557-657) conta
262                        Signaling through the IL-4R alpha-chain (IL-4Ralpha) is crucial for the develo
263 tive and antiapoptotic signaling through the IL-4R in 32D cells; however their role in regulating nor
264 duced by NKT cells and signaling through the IL-4R-STAT6 pathway, are necessary for down-regulation o
265 rotein produce IL-4 mutants that bind to the IL-4R alpha-chain with high affinity, but do not induce
266     The IL-4 toxin binds specifically to the IL-4R and is highly cytotoxic to glioblastoma cells, as
267 different signalling pathways coupled to the IL-4R complexes and examine the possible mechanisms of D
268 f STAT6 by inhibiting its recruitment to the IL-4R.
269 TAT6 proteins induced by IL-4 binding to the IL-4R.
270 IL-13, the only other cytokine that uses the IL-4R-STAT6 pathway.
271 te gamma'-chain, which can interact with the IL-4R alpha chain to mediate signaling, is expressed on
272 +) and CD8(+) T cells were detected with the IL-4R antagonist adjuvanted strategy compared to the una
273 e specifically coimmunoprecipitated with the IL-4R as well as with phosphatidylinositol 3-kinase (p85
274 (IL-21R) shows significant homology with the IL-4R, and CD4+ Th2 cells are an important source of IL-
275 paired IL-4/IL-13 activation of AAMs through IL-4R types 1 and 2.
276  IL-4 and lose the ability to signal through IL-4R.
277                       IL-4 signaling through IL-4R alpha/gamma(c) suppresses Ca2T6 and SPRR gene expr
278 14, CD54, FcgammaR1, FcalphaR, CD120b, TLR5, IL-4R, CCR1, p47(phox), p40(phox), IL-8, CXCL1, Nramp1,
279 ace IL-4 receptors (IL-4R) and IL-4 binds to IL-4R on one cell line studied with low affinity ((k)d =
280 otoxin [IL4(38-37)-PE38KDEL] is cytotoxic to IL-4R-expressing cells, we tested whether primary GBM ex
281 d to be highly and specifically cytotoxic to IL-4R-positive head and neck cancer cells, as determined
282 atically reduced in both anti-IL-10R-treated IL-4R alpha(-/-) mice and IL-4R alpha x IL-10 double kno
283 ion much less efficiently than did wild-type IL-4R, requiring 150-fold more IL-4 to reach maximal CD2
284                Moreover, VIL-4 seemed to use IL-4R alpha for signaling and activation, as the VIL-4-i
285 alpha), suggesting enhanced responses of V50 IL-4R when IL-4 is limiting.
286  of phosphorylated STAT6 observed in the V50-IL-4R(alpha)-expressing cells.
287 IL-4 triggers the apoptosis of Th1 cells via IL-4R alpha/IL-13R alpha 1, thus explaining the Th2 bias
288 in BALB/c strain mice and that signaling via IL-4R can be an important factor in the generation of pr
289                                      Whereas IL-4R antagonist blocked responses to both cytokines, sh
290 em during the acute phase in WT mice whereas IL-4R(-/-) animals expressed higher levels of IL-6 and I
291 on occurs through Ca2+ mobilization, whereas IL-4R down-regulation occurs through a distinct Stat6-de
292                             However, whether IL-4R are expressed in brain tumors in situ has not been
293 of IL-13 or IL-13R110Q and IL-13Ralpha1 with IL-4R using surface plasmon resonance and time-resolved
294  gene-subsets and individual genes (FLG with IL-4R and CCL17; r < -0.4, P < .05).
295 (IL-13R alpha 1), which heterodimerizes with IL-4R alpha.
296 amma-chain, which is known to be shared with IL-4R in immune cells.
297 cores stabilized among patients treated with IL-4R 1, 500 microg, despite abrupt withdrawal of cortic
298                               Treatment with IL-4R produced significant improvement in FEV(1) on Day
299 mbilical cord methylation of CpG loci within IL-4R with atopic eczema at 12 months (median ratio 1.02
300 lpha and an IL-4 double mutein (R121D/Y124D, IL-4R antagonist) on IL-4- and IL-13-mediated responses.

 
Page Top